Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.49 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888854 | 0.83 | HDAC6 (0.61) | RENCES1CES2AKR1B1HDAC6 | |
| SCHEMBL17732626 | 0.83 | REN (0.71) | RENCES1CES2AKR1B1HDAC6 | |
| SCHEMBL195224 | 0.81 | LMNA (0.58) | RENCES1CES2AKR1B1MEN1 | |
| SCHEMBL31296669 | 0.79 | LMNA (0.51) | RENCES1CES2AKR1B1MEN1 | |
| SCHEMBL19405101 | 0.78 | TDP1 (0.69) | RENCES1CES2AKR1B1MEN1 | |
| SCHEMBL27822859 | 0.77 | CES1 (0.58) | RENCES1CES2AKR1B1HDAC6 | |
| SCHEMBL3456186 | 0.76 | LMNA (0.68) | RENMEN1KMT2ATRPM8 | |
| SCHEMBL16909073 | 0.76 | ALOX5 (0.58) | HDAC6HDAC8HDAC1HDAC3HDAC4 | |
| SCHEMBL13191459 | 0.76 | POLB (0.57) | RENAKR1B1ALOX5 | |
| SCHEMBL6858497 | 0.76 | CES1 (0.56) | RENCES1CES2AKR1B1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027332-B1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | DUAN JINGWU (US) | 2003-07-17 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | REN 533/4885CES1 205/4885CES2 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.